Clearside Biomedical, Inc. (NASDAQ:CLSD) Short Interest Down 26.5% in February

Clearside Biomedical, Inc. (NASDAQ:CLSD) was the target of a significant decline in short interest in the month of February. As of February 15th, there was short interest totalling 571,300 shares, a decline of 26.5% from the January 31st total of 777,800 shares. Based on an average trading volume of 246,400 shares, the days-to-cover ratio is presently 2.3 days.

Clearside Biomedical Stock Up 1.3 %

CLSD stock traded up $0.01 during trading hours on Tuesday, hitting $0.80. The company’s stock had a trading volume of 401,256 shares, compared to its average volume of 397,266. The company has a market capitalization of $60.68 million, a PE ratio of -1.78 and a beta of 2.10. Clearside Biomedical has a 12 month low of $0.77 and a 12 month high of $2.12. The stock has a 50 day moving average price of $0.97 and a two-hundred day moving average price of $1.06.

Institutional Trading of Clearside Biomedical

Several large investors have recently added to or reduced their stakes in CLSD. Johnson & Johnson bought a new stake in Clearside Biomedical in the third quarter worth approximately $105,000. Geode Capital Management LLC boosted its holdings in shares of Clearside Biomedical by 8.8% during the 3rd quarter. Geode Capital Management LLC now owns 731,386 shares of the company’s stock worth $929,000 after buying an additional 59,089 shares during the period. Northern Trust Corp boosted its holdings in shares of Clearside Biomedical by 24.0% during the 4th quarter. Northern Trust Corp now owns 165,499 shares of the company’s stock worth $157,000 after buying an additional 32,048 shares during the period. Finally, Investor s Fiduciary Advisor Network LLC bought a new stake in shares of Clearside Biomedical during the 4th quarter worth $32,000. 18.75% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of Clearside Biomedical in a report on Thursday, November 14th. Chardan Capital reaffirmed a “buy” rating and set a $6.00 price objective on shares of Clearside Biomedical in a research report on Friday, November 15th. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price objective on shares of Clearside Biomedical in a research report on Wednesday, November 13th. Finally, StockNews.com raised shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a research report on Thursday, December 12th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $5.33.

About Clearside Biomedical

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.